US EditionLantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging ...
3 Articles
3 Articles
Lantheus and GE HealthCare sign licensing agreement for PYLARIFY in Japan
Lantheus Holdings (LNTH) and GE HealthCare (GEHC) announced on Wednesday an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize piflufolastat F18 in Japan for prostate cancer diagnostics.
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging ...
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY®…
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY (Piflufolastat F 18) in Japan
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is […] The post Lantheus and GE HealthCare Announce Exclusi…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
